<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00083135</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000363631</org_study_id>
    <secondary_id>P01CA081403</secondary_id>
    <secondary_id>N2000-01</secondary_id>
    <nct_id>NCT00083135</nct_id>
  </id_info>
  <brief_title>N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation</brief_title>
  <official_title>I-MIBG Escalating Dose Rapid Sequence Double Infusion Followed By Autologous Stem Cell Infusion For Refractory Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving iodine I 131 metaiodobenzylguanidine (^131I-MIBG) may kill neuroblastoma&#xD;
      cells by delivering radiation directly to the tumor. A stem cell transplant using the&#xD;
      patient's stem cells may be able to replace blood-forming cells destroyed by radiation&#xD;
      therapy.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of a double infusion&#xD;
      of ^131I-MIBG followed by autologous stem cell transplantation in treating patients with&#xD;
      refractory neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated red marrow radiation dose delivered and associated toxic&#xD;
           effects of escalating activity of iodine I 131 metaiodobenzylguanidine (^131I-MIBG)&#xD;
           followed by autologous hematopoietic stem cell transplantation in patients with&#xD;
           refractory neuroblastoma.&#xD;
&#xD;
        -  Determine the number of days after stem cell transplantation to achieve absolute&#xD;
           neutrophil count ≥ 500/mm^3 for 3 days and platelet count ≥ 20,000/mm^3 for 3 days&#xD;
           (without transfusions) in patients treated with this regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the response rate in patients treated with this regimen, based on lesions&#xD;
           measurable by CT or MRI at study entry, patients with ^131I-MIBG scan-positive lesions&#xD;
           only, and patients with minimal residual tumor in bone marrow who have complete response&#xD;
           by immunocytology and morphology.&#xD;
&#xD;
        -  Determine the tumor absorbed radiation dose in patients with measurable soft tissue&#xD;
           lesions treated with this regimen.&#xD;
&#xD;
        -  Correlate, if possible, TP53 mutations with response in patients with accessible bone&#xD;
           marrow tumor treated with ^131I-MIBG.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study.&#xD;
&#xD;
        -  Iodine I 131 metaiodobenzylguanidine (131I-MIBG) therapy: Patients receive^131I-MIBG IV&#xD;
           over 2 hours on days 0 and 14.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of ^131I-MIBG until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Stem cell transplantation therapy: Patients undergo autologous peripheral blood stem&#xD;
           cell transplantation on day 28. Patients receive filgrastim (G-CSF) IV over 1 hour OR&#xD;
           subcutaneously daily beginning on day 28 and continuing until blood counts recover.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 9-18 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Neuroblastoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iobenguane I 131</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of neuroblastoma&#xD;
&#xD;
               -  Confirmed by at least 1 of the following methods:&#xD;
&#xD;
                    -  Histology&#xD;
&#xD;
                    -  Clumps of tumor cells in bone marrow with elevated urinary catecholamine&#xD;
                       metabolites&#xD;
&#xD;
               -  High-risk disease&#xD;
&#xD;
                    -  Poor response to induction therapy OR relapse defined by any of the&#xD;
                       following:&#xD;
&#xD;
                         -  No response, stable disease, or mixed response after a minimum of 3&#xD;
                            prior courses of chemotherapy&#xD;
&#xD;
                         -  More than 100 tumor cells per 10^5 nucleated cells on bone marrow&#xD;
                            immunocytology after at least 3 prior courses of chemotherapy&#xD;
&#xD;
                         -  Progressive disease at any time during or after therapy&#xD;
&#xD;
                         -  Patients with massive bone marrow invasion (more than 50% replacement&#xD;
                            of bone marrow by tumor cells) are allowed&#xD;
&#xD;
          -  Must have positive iodine I 131 metaiodobenzylguanidine (^131I-MIBG) within the past 6&#xD;
             weeks or subsequent to any other prior antitumor therapy delivered within the past 6&#xD;
             weeks&#xD;
&#xD;
          -  Must meet the following criteria for minimum number of autologous stem cells:&#xD;
&#xD;
               -  Unpurged peripheral blood stem cells (PBSC)&#xD;
&#xD;
                    -  Minimum of 1,500,000/mm^3 CD34-positive cells/kg&#xD;
&#xD;
                    -  Collected products must have &lt; 1 tumor cell/100,000 normal cells by&#xD;
                       immunocytology&#xD;
&#xD;
               -  PBSC purged with immunomagnetic beads&#xD;
&#xD;
                    -  Minimum of 1,000,000/mm^3 viable CD34-positive cells/kg&#xD;
&#xD;
                    -  Collected products must have &lt; 1 tumor cell/100,000 normal cells by&#xD;
                       immunocytology&#xD;
&#xD;
               -  CD34-positive selected PBSC products are not allowed&#xD;
&#xD;
               -  Patients who had PBSC collected previously with no immunocytological testing&#xD;
                  available may use those products provided bone marrow is tumor free by bilateral&#xD;
                  bone marrow aspirate AND biopsy for morphology is performed within 4 weeks before&#xD;
                  PBSC collection&#xD;
&#xD;
               -  Patients with no tumor involvement in bone marrow at diagnosis and PBSC&#xD;
                  collection before any disease progression do not require documentation of&#xD;
                  negative bone marrow morphology&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  1 to 30&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Less than 1 year&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm^3 (without transfusion)&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 5 times normal&#xD;
&#xD;
          -  Bilirubin &lt; 2 times normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Glomerular filtration rate OR 12-hour creatinine clearance ≥ 60 mL/min/1.73m^2&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction ≥ 55% by echocardiogram or MUGA OR&#xD;
&#xD;
          -  Fractional shortening ≥ 30% OR above lower limit of normal by echocardiogram&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  Normal lung function&#xD;
&#xD;
          -  No dyspnea at rest&#xD;
&#xD;
          -  No exercise intolerance&#xD;
&#xD;
          -  No oxygen requirement&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to cooperate physically and psychologically with radiation isolation&#xD;
&#xD;
          -  No disease of any major organ system that would preclude study participation&#xD;
&#xD;
          -  No active infection requiring antivirals, antibiotics, or antifungals&#xD;
&#xD;
          -  No weight that would require exceeding a maximum total allowable dose of ^131I-MIBG&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 2 weeks since prior biologic or other non-myelosuppressive therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior chemotherapy&#xD;
&#xD;
          -  More than 3 months since prior myeloablative therapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 months since prior craniospinal, total abdominal, or whole lung&#xD;
             radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy to any site&#xD;
&#xD;
          -  No prior total body irradiation&#xD;
&#xD;
          -  No prior radiotherapy to &gt; 25% of bone marrow&#xD;
&#xD;
          -  No prior ^131I-MIBG&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  Concurrent antifungal therapy allowed provided culture and biopsy are negative in&#xD;
             suspected radiographic lesions&#xD;
&#xD;
          -  Prior re-induction therapy for recurrent tumor allowed&#xD;
&#xD;
          -  No concurrent antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent hemodialysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine K. Matthay, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregory Yanik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John M. Maris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-0700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM. Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol. 2009 Mar 1;27(7):1020-5. doi: 10.1200/JCO.2007.15.7628. Epub 2009 Jan 26.</citation>
    <PMID>19171714</PMID>
  </results_reference>
  <results_reference>
    <citation>Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, Jackson HA, Mari Aparici C, Carlson D, Maris J, Hawkins R, Matthay KK. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009 Nov 10;27(32):5343-9. doi: 10.1200/JCO.2008.20.5732. Epub 2009 Oct 5.</citation>
    <PMID>19805691</PMID>
  </results_reference>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>May 14, 2004</study_first_submitted>
  <study_first_submitted_qc>May 14, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2004</study_first_posted>
  <last_update_submitted>October 14, 2010</last_update_submitted>
  <last_update_submitted_qc>October 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Katherine K. Matthay, M.D.</name_title>
    <organization>UCSF School of Medicine</organization>
  </responsible_party>
  <keyword>recurrent neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

